BioCentury | Oct 17, 2020
Finance

Praxis sees strongest first-day among trio of IPOs as NASDAQ nears $16B raised in fresh paper

Among a trio of clinical biotechs pricing IPOs ahead of Friday’s NASDAQ session, demand was highest for Praxis as the company posted a 46% gain, while the reception was more muted for Aligos and Tarsus...
BioCentury | Oct 6, 2020
Politics, Policy & Law

Treating Trump & BMS’s $13B MyoKardia buy: a BioCentury podcast

In the latest BioCentury This Week podcast, BioCentury’s editors discuss access to Regeneron’s experimental COVID-19 therapy, fallout from last week’s House drug pricing hearings, Bristol Myers’ heart pumping $13 billion takeout of MyoKardia and the outlook...
BioCentury | Oct 2, 2020
Finance

Election volatility may drive investors toward low-risk opportunities in 4Q

The increasing likelihood of a contested U.S. presidential election means the markets could be in for a high dose of volatility in 4Q20, pushing the pause button on a record year for IPOs and sending...
BioCentury | Jul 30, 2020
Finance

July 28 Quick Takes: Venture round reveals for Omega, Praxis, HaiHe; plus trio of NASDAQ IPO filings, Atsena’s debut, La Jolla-Tetraphase

Omega reveals venture tally Omega Therapeutics Inc. announced it has raised $85 million since its 2016 launch by Flagship Pioneering to support development of therapies targeting chromatin structures. The funding includes a series A round...
BioCentury | Jun 13, 2020
Management Tracks

Sawyers to head AACR next year; plus Quell, CalciMedica, Bigfoot, Celyad, Praxis, Affimed and more

The American Association for Cancer Research elected Charles Sawyers as president; he will assume the role during AACR’s 2021 meeting, which will take place in Washington on April 9-14. Sawyers is chair of Memorial Sloan...
BioCentury | May 30, 2020
Finance

GV’s 2020 viewpoint

GV thinks its funding structure will allow it to weather the year’s financial storms and keep working to plug gaps in the healthcare system. The venture arm of Alphabet Inc. (NASDAQ:GOOG) has $5 billion under...
BioCentury | May 23, 2020
Emerging Company Profile

Praxis: connecting the neurological dots

Praxis’ neurology pipeline emerged from genetic data that found neuronal imbalances to be at the root of several disorders that were previously thought to be unrelated. The company debuted this month with $100 million in...
BioCentury | Mar 6, 2020
Finance

Biotechs cede ground to end wild week of trading

Biotechs will have to wait until next week to see if ongoing market volatility amid uncertainty related to the COVID-19 outbreak will allow Imara, the last company remaining in the NASDAQ IPO queue, to price...
BioCentury | Jan 23, 2020
Company News

Thirteen years from founding, Epizyme scores first FDA approval

...EZH2 and DOT1L, to treat cancer. In 2012, Epizyme started a Phase I trial of DOT1L...
BioCentury | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

One hundred days after taking the helm as CEO, Paul Hudson has outlined a plan to get Sanofi to 30% margins by 2022 that hinges largely on the success of Dupixent and five other priority...
Items per page:
1 - 10 of 609